Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 year old~* Not pregnant or breast feeding~* Cannabis abuse or dependence diagnosis (DSM-IV)~* Acceptance of the trial and consent signed, validated by ethic committee~* Patient affiliated to social insurance care~Exclusion Criteria:~* Contraindication to N-acetylcystein : allergic to N-acetylcystein, severe allergic illness, PHENYLCETONURIA, lactose intolerance, gastro-duodenal ulcer.~* Severe somatic disease not stabilized : diabetes, epilepsia, recent myocardial infarcts, asthma.~* Severe mental disease not stabilized : schizophrenia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Experimental : N-acetylcystein (Type: EXPERIMENTAL): N-acetylcystein and placebo doses will be increased if craving decreases \<25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h
- Placebo Comparator (Type: PLACEBO_COMPARATOR): N-acetylcystein and placebo doses will be increased if craving decreases \<25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h

Based on this trial design, predict the completion outcome and termination type (if applicable).